Free tool
Rare disease stocks
We cover 7 companies grouped under the Rare disease theme. The median market value in the group is $575.28M. Across the group, the median move over the past trading day is +0.05%. Price change over the past year runs from −1.0% to +233.2% across the middle 80 percent of the group, with a median of +42.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
7 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +40.77% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +15.03% |
| 0QNA.L | Basilea Pharmaceutica AG | $762.45M | Small cap | +41.96% |
| 0KBU.L | Omeros Corporation | $575.28M | Small cap | +332.86% |
| 0OB3.L | Valneva SE | $270.41M | Small cap | −25.05% |
| XUP.DE | Genfit S.A. | $258.22M | Small cap | +166.82% |
| 0IIM.L | Esperion Therapeutics, Inc. | $61.56M | Micro cap | +44.65% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.